CD86 and Alzheimer disease: Thus, these results confirm that PEA is able to modulate the phenotype of MDDCs also in AD conditions, inducing the upregulation of co-stimulatory molecules CD83, CD80 and CD86, as well as HLA class II molecules specifically in immature ADMDDCs, mainly triggering their shift towards maturation.